CAPecitabine TEMozolomide (CAPTEM). Archives

25 Aug 2024

12 Comments

Chemo or not Chemo – that is the question

TreatmentAfinitor, Antineoplastic therapy, CAPecitabine TEMozolomide (CAPTEM)., Carboplatin, Chemotherapy, Cisplatin, Cytotoxic, Everolimus, Fluorouracil (5-FU), Hormone therapy, Lanreotide, Mammalian target of rapamycin (mTOR) inhibitor, mTOR inhibitor, Octreotide, Oxaliplatin (Eloxatin), Protein kinase inhibitor, Somatostatin analogues, Streptozotocin (Zanosar), Sunitinib (Sutent)

I often see certain drugs for the treatment of Neuroendocrine Tumours (NETs) described as "chemotherapy". Although since I wrote the first edition of this post in 2016, I don't see it as much today in 2024. Education is a wonderful thing! I think there must be some confusion with more modern drugs which are more targeted and work in a different way to Chemotherapy. According to Mayo Clinic: "In many ways, cytotoxic chemotherapy is "targeted" at specific molecules that regulate progression through the cell cycle; however, these targets are generally not specific for tumour cells. Because systemic cytotoxic chemotherapy targets…

21 Apr 2024

By Ronny Allan

9 Comments

Chemotherapy for Neuroendocrine Neoplasms

Treatment5-Fluorouracil (5-FU), Afinitor, Cancer research, Capecitabine (Xeloda), CAPecitabine TEMozolomide (CAPTEM)., CAPTEM, Carboplatin, Chemotherapy, Cisplatin, Etoposide, Everolimus, FCarboSt, FOLFIRI, FOLFOX, High Grade NEC, Irinotecan (Campto), Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN), Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Paclitaxel (Taxol), Poorly differentiated, PRRT, Somatostatin analogues, Streptozotocin (Zanosar), Sunitinib (Sutent), Temozolomide (Temodal), Vepesid), Well differentiated, XELOX. Oxaliplatin (Eloxatin)

By Ronny Allan – Living with Neuroendocrine Cancer Chemotherapy has a long and complicated history in the management of Neuroendocrine Neoplasms (NENs) (an umbrella term for both Neuroendocrine Tumours (NET) and Neuroendocrine Carcinomas (NEC)). Unlike many other cancers, most well‑differentiated NETs are relatively resistant to traditional cytotoxic chemotherapy. However, chemotherapy remains an important option for specific subtypes, particularly higher‑grade disease, and certain anatomical sites. There's a myth that circulates the NET patient groups along the lines of "chemotherapy does not work for NETs". That's not entirely true or at best totally out of context. However, it's true to say that…

15 Jun 2022

By Ronny Allan

0 Comments

CAPTEM for Neuroendocrine Tumours

Clinical Trials and Research, TreatmentAdvanced neuroendocrine cancer, Capecitabine (Xeloda), CAPecitabine TEMozolomide (CAPTEM)., CAPTEM, Chemotherapy, Clinical trial, Pancreatic NET (PanNET), Temozolomide (Temodal)

What is CAPTEM? Capecitabine is an oral drug used alone or with other drugs to treat certain types of colorectal cancer and breast cancer. It is also being studied in the treatment of other types of cancer including in combination with a second drug. Capecitabine is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Also called Xeloda. Note -Capecitabine is an oral Oral 5-FU prodrugs which are medications designed to be taken by mouth and converted into the active chemotherapy agent 5-flourouracil (5-FU) within the body, aiming for higher tumour selectivity and…

07 Mar 2022

By Ronny Allan

0 Comments

Clinical Trial: Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Clinical Trials and Research, TreatmentCAPecitabine TEMozolomide (CAPTEM)., CAPTEM, Chemotherapy, NETest, Pancreatic NET (PanNET), Surgery

An interesting trial centred on SW USA. The use of CAPTEM following surgery in high-risk pancreatic NETs (G2/G3 well-differentiated). Also includes the use of NETest at 3 time points, which is very interesting considering the recent withdrawal of Chromogranin A from US NET Guidelines. (Read about NETest here). Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (S2104) is a recently activated National Clinical Trials Network randomized phase II trial designed to compare CAPTEM chemotherapy versus observation following resection of pNETs (see Figure 2). Patients with well-differentiated grade 2 or 3 (Ki-67 up…

07 Mar 2021

By Ronny Allan

0 Comments

Treatment for Neuroendocrine Cancer – a summary for patients

Treatment5-Fluorouracil (5-FU), Atezolizumab (Tecentriq), Avelumab (Bavencio), Capecitabine (Xeloda), CAPecitabine TEMozolomide (CAPTEM)., Chemotherapy, Cisplatin, Cisplatin/Etoposide, Cryoablation, Cyberknife, Etoposide, External beam radiotherapy, FOLFIRI, FOLFOX, Gamma knife, Interferon alpha (IFNα), Irinotecan (Campto), Irreversible electroporation (IRE), Lanreotide, Liver directed therapy, Lu-177, Lutathera, NanoKnife®, Nivolumab (Opdivo), Octreotide (Octreotide acetate), Opdivo (Nivolumab), Paclitaxel (Taxol), Pembrolizumab (Keytruda), Peptide receptor radionuclide therapy (PRRT), Proton beam therapy, Radiation therapy, Somatostatin analogues, Somatostatin receptors (SSTR), Somatuline Autogel (US: depot), Stereotactic body radiotherapy (SBRT), Stereotactic radiosurgery (SRS), Streptozotocin (Zanosar), Surgery, Targeted therapy, Temozolomide (Temodal), Thorson-Bioerck syndrome, Tumour mutational burden (TMB), Vepesid), Watchful waiting

1. Scope This summary provides an overview of the types of therapy known for treating Neuroendocrine Cancer. They will have been approved at least by one national or regional approval agency, may not be available or approved in your own country; and may appear in clinical guidelines for the treatment of Neuroendocrine Cancer. Clinical trials will not be covered, although it's noted that some of the approved treatments listed may be in follow on trials either to prove new coverage or used in combination with another drug. For a list of clinical trials covered by the author, click here.…

19 May 2017

By Ronny Allan

5 Comments

ASCO 2017 – Let’s talk about NETs #ASCO17

Clinical Trials and Research5-HIAA, Advanced neuroendocrine cancer, American Society of Clinical Oncology (ASCO), Bone metastases, Cancer of unknown primary (CUP), CAPecitabine TEMozolomide (CAPTEM)., Carcinoid crisis, Carcinoid syndrome, Carcinoid tumour, Chemotherapy, Chromogranin A (CgA), CLARINET, Comorbidity, DUNE trial, Durvalumab, ELECT study, Flushing, Ga68-OPS202, Grading, Hormones, Incurable cancer, Ki-67, Lanreotide, Liver metastases, Metastatic Neuroendocrine Cancer, Molecular markers, NETest, Neuroendocrine, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Octreotide, Pancreatic NET (PanNET), Peptide receptor radionuclide therapy (PRRT), Poorly differentiated, Pre-existing condition, PRRT, Quality of LIfe (QoL), Small intestine NET (SI NET), Somatostatin analogues, Stage, Surgery, Theranostics, Well differentiated

ASCO (American Society of Clinical Oncology) is one of the biggest cancer conferences in the world normally bringing together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. As Neuroendorine Tumors is on a roll in terms of new treatments and continued research, we appear to be well represented with over 20 'extracts' submitted for review and display. This is fairly complex stuff but much of it will be familiar to many. I've filtered and extracted all the Neuroendocrine stuff into one list providing you with an…

20 May 2016

By Ronny Allan

0 Comments

Clinical Trial: PRRT and CAPTEM combination therapy

Clinical Trials and ResearchCapecitabine (Xeloda), CAPecitabine TEMozolomide (CAPTEM)., CAPTEM, CONTROLNETS, Peptide receptor radionuclide therapy (PRRT), PRCRT, PRRT, Temozolomide (Temodal)

Updated 2026: A more recent, mature publication from the same Australian CONTROL NET programme has confirmed the earlier signal: combining PRRT with CAPTEM produces high response rates, particularly in pancreatic NETs, but at the cost of substantially increased haematologic toxicity and no clear, durable survival advantage strong enough to change guidelines. Highlights Efficacy outcomes from PRRT+CAPTEM in NENs remain unclear. PRRT/CAPTEM was feasible and well tolerated in this randomized trial. SBNETS: No PFS difference between PRRT/CAPTEM and PRRT. PNETs: PFS/ORR for PRRT/CAPTEM numerically higher than CAPTEM on extended follow-up. Randomized studies in uncommon tumours are essential to optimise practice. Interesting…

Tag: CAPecitabine TEMozolomide (CAPTEM).